2014
HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges
Buza N, Roque DM, Santin AD. HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. Archives Of Pathology & Laboratory Medicine 2014, 138: 343-50. PMID: 24576030, DOI: 10.5858/arpa.2012-0416-ra.Peer-Reviewed Original ResearchConceptsEndometrial carcinomaHER2/neuPromising therapeutic targetHER2 testingClinical responseTherapeutic targetHumanized monoclonal immunoglobulin G1 antibodyMonoclonal immunoglobulin G1 antibodyUterine serous carcinomaImmunoglobulin G1 antibodyNovel therapeutic strategiesEndometrial cancerSerous adenocarcinomaSerous carcinomaCase reportDiagnostic challengeHER2 overexpressionPathogenetic featuresClinical studiesG1 antibodyTherapeutic strategiesCarcinomaTherapeutic efficacyStandardized criteriaTherapy
2011
erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy
ElSahwi KS, Santin AD. erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy. Obstetrics And Gynecology International 2011, 2011: 128295. PMID: 21876697, PMCID: PMC3159302, DOI: 10.1155/2011/128295.Peer-Reviewed Original ResearchUterine serous adenocarcinomaERBB2 overexpressionEndometrial cancerCommon female genital tract malignancyFemale genital tract malignanciesType I endometrial cancerGenital tract malignanciesUterine serous cancerViable treatment optionSerous cancerStandard chemotherapyWorse survivalLymph nodesTrastuzumab therapyBetter prognosisDistant metastasisSerous adenocarcinomaTreatment optionsCase reportRecurrent casesBreast cancerHumanized mAbTrastuzumab activityType II variantCancer relapse